Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Renal denervation in uncontrolled hypertension: the story continues to unfold

In The Lancet David E Kandzari and colleagues report the 6 month efficacy and safety results from the randomised, single-blind, sham-controlled SPYRAL HTN-ON MED proof-of-concept trial.1 The investigators noted that on average renal denervation had a blood pressure lowering effect in patients with uncontrolled hypertension who were on antihypertensive medication.1 Office and 24 h ambulatory blood pressure decreased significantly from baseline to 6 months in the renal denervation group (mean baseline-adjusted treatment differences in 24 h systolic blood pressure −7·0 mm Hg, 95% CI −12·0 to −2·1, p=0·0059; 24 h diastolic blood pressure −4·3 mm Hg, −7·8 to −0·8, p=0·0174; office systolic blood pressure −6·6 mm Hg, −12·4 to −0·9, p=0·0250; and office diastolic blood pressure −4·2 mm Hg, −7·7 to −0·7, p=0·0190).